Lanthionine synthetase c-like 2-based therapeutics

A compound comprising formula Z—Y-Q-Y′—Z′ or a pharmaceutically acceptable salt or ester thereof,

• wherein:
• Z is:
• Y is:
• Q is piperazine-1,4-diyl;
• 2,5-diazabicyclo[2.2.1]heptane-2,5-diyl;
• 2,5-diazabicyclo[2.2.2]octane-2,5-diyl;
• 1,4-diazepane-1,4-diyl;
• benzene-1,4-diamine-N1,N4-diyl;
• ethane-1,2-diamine-N1,N2-diyl;
• N1,N2-dialkylethane-1,2-diamine-N1,N2-diyl;
• propane-1,3-diamine-N1,N3-diyl;
• N1,N3-dialkylpropane-1,3-diamine-N1,N3-diyl;
• 1,4-diaminoanthracene-9,10-dione-1,4-diyl;
• C6 arene-1,4-diamine-N1,N4-diyl wherein the arene is substituted with one to four substituents in the 2, 3, 5, or 6 positions and wherein the substituents are independently selected from the group consisting of —C(O)O(C1 to C6)alkyl, OH, O(C1 to C6)alkyl, (C1 to C6)alkyl, CF3, F, Cl, and Br;
• or substituted piperazine-1,4-diyl wherein the piperazine is substituted with one to eight substituents in the 2, 3, 5, or 6 positions and wherein the substituents are independently selected from the group consisting of (C1 to C6)alkyl, aryl, aryl(C1 to C6)alkyl, C(O)OH, and C(O)O(C1 to C6)alkyl;
• Y′ is:
• or a single bond;
• and
• Z′ is:
• or R5;
• wherein:
• Y′ is a single bond only when Z′ is R5;
• A1 and A1′ are each independently N, N(C1 to C6)alkyl, O, S, or CR6;
• A2 and A2′ are each independently N or CR7;
• A3 and A3′ are each independently NR8, O, or S;
• A4 and A4′ are each independently N or CR9;
• A5 and A5′ are each independently N or CR10;
• A6 and A6′ are each independently N or CR11;
• R1, R1′, R2, R2′, R3, R3′, R4, R4′, R5, R6, R7, R8, R9, R10, and R11 are each independently selected from the group consisting of hydrogen;
• alkyl;
• halo;
• trifluoromethyl;
• dialkylamino wherein each alkyl is independently selected;
• —NH2;
• alkylamino;
• arylalkyl;
• heteroarylalkyl;
• heterocycloalkyl;
• substituted heterocycloalkyl substituted with 1 to 2 substituents independently selected from the group consisting of —C(O)OH, —C(O)O(C1 to C6)alkyl, (C1 to C6)alkyl, —CF3, F, Cl, and Br;
• and substituted heteroarylalkyl;
• wherein the substituted heteroarylalkyl is substituted with 1 to 3 substituents independently selected from the group consisting of —NH2;
• —NH(C1 to C6)alkyl;
• —N((C1 to C6)alkyl)2 wherein each alkyl is independently selected;
• alkyl;
• halo;
• aryl;
• substituted aryl substituted with 1 to 3 substituents independently selected from the group consisting of —SO2R12, —OR13, -halo, —CN, —CF3, aminoalkyl-, —S(O)R14, and alkyl;
• heterocycloalkyl;
• heteroaryl;
• substituted aryl substituted with 1 to 3 substituents independently selected from the group consisting of alkyl, —CF3, F, Cl, and Br;
• alkylamino-;
• heterocycloalkyl-alkyl-amino-;
• alkylaminoalkylamino-;
• —NHC(O)OR15;
• —NHC(O)NR16R17;
• —C(O)NR16R17;
• and substituted heteroaryl substituted with 1 to 3 substituents selected from the group consisting of alkyl, halo, CN, NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2 wherein each alkyl is independently selected, —CF3, and substituted aryl substituted with 1 to 3 substituents independently selected from the group consisting of —S(O)2R15 and —CN;
• wherein R12, R13, R14, R15, R16, and R17 are each independently selected from the group consisting of C1-C6 alkyl, dialkylamino comprising independently selected C1-C6 alkyl, —NH2, alkylamino, heterocycloalkyl, and substituted heterocycloalkyl substituted with one to two substituents independently selected from the group consisting of —C(O)O(C1-C6 alkyl) and C1-C6 alkyl.